Indobufen

DRUG5 trials

Sponsors

Pfizer, Asan Medical Center, Beijing Tiantan Hospital, Henan Institute of Cardiovascular Epidemiology, Shanghai Zhongshan Hospital

Conditions

Antiplatelet DrugsAspirinAtrial FibrillationCoronary Artery DiseaseHealthyIndobufenIschemic StrokeStable Coronary Heart Disease

Phase 1

Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent

Asan Medical CenterHealthy

Start: 2010-01-31Target: 12Updated: 2010-11-10

Phase 3

S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation

CompletedNCT00244426

PfizerAtrial Fibrillation

Start: 2000-12-31End: 2008-04-30Updated: 2018-12-19

Phase 4

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

CompletedNCT03871517

Beijing Tiantan HospitalAspirin, Indobufen, Ischemic Stroke

Start: 2019-06-03End: 2022-12-01Updated: 2023-01-09

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

RecruitingNCT06451198

Shanghai Zhongshan HospitalAntiplatelet Drugs, Coronary Artery Disease

Start: 2025-05-19End: 2028-12-31Target: 2846Updated: 2026-03-12

Unknown Phase

Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease

WithdrawnNCT04308551

Henan Institute of Cardiovascular EpidemiologyStable Coronary Heart Disease

Start: 2024-12-30End: 2026-12-30Updated: 2024-11-20

Related Papers

Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.

2023-04-2720 citations

Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial

Stroke and Vascular Neurology2022-04-077 citations